Immatics awaits Phase 3 melanoma data; pivotal for German biotech

Immatics, a German biotech, is approaching a critical juncture as it awaits Phase 3 results for its lead cancer candidate in melanoma. The outcome will determine its ability to secure approval and validate its platform. Uncertainty remains on efficacy and regulatory path.